Bioleaders (KOSDAQ:A142760) - Share price, News & Analysis

A142760 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

A142760 Stock Overview

Bioleaders Corporation engages in the medicine and consumer business in South Korea.

Risk Analysis

Earnings have declined by 20.4% per year over past 5 years

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

Bioleaders Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bioleaders
Historical stock prices
Current Share Price	₩6,430.00
52 Week High	₩18,450.00
52 Week Low	₩5,410.00
Beta	0.41
1 Month Change	-24.09%
3 Month Change	-44.81%
1 Year Change	-9.69%
3 Year Change	-38.76%
5 Year Change	10.86%
Change since IPO	-54.72%

Recent News & Updates

Feb 16

Bioleaders' (KOSDAQ:142760) Shareholders Are Down 47% On Their Shares

As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain...

Shareholder Returns

	A142760	KR Biotechs	KR Market
7D	4.7%	-2.8%	0.006%
1Y	-9.7%	-39.8%	-15.8%

Return vs Industry: A142760 exceeded the KR Biotechs industry which returned -39.8% over the past year.

Return vs Market: A142760 exceeded the KR Market which returned -15.8% over the past year.

Price Volatility

Is A142760's price volatile compared to industry and market?
A142760 volatility
A142760 Average Weekly Movement	7.9%
Biotechs Industry Average Movement	6.4%
Market Average Movement	5.5%
10% most volatile stocks in KR Market	10.3%
10% least volatile stocks in KR Market	3.2%

Stable Share Price: A142760 is more volatile than 75% of KR stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: A142760's weekly volatility has decreased from 14% to 8% over the past year, but is still higher than 75% of KR stocks.

About the Company

Founded	Employees	CEO	Website
1999	54	Andy Chul	https://www.bioleaders.co.kr

Bioleaders Corporation engages in the medicine and consumer business in South Korea. The company offers P53, a target anti-cancer drug. Its pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment vaccine of cervical cancer; BLC-H03, an H. vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 for the treatment of Duchenne muscular dystrophy.

Bioleaders Fundamentals Summary

How do Bioleaders's earnings and revenue compare to its market cap?
A142760 fundamental statistics
Market Cap	₩196.55b
Earnings (TTM)	-₩19.77b
Revenue (TTM)	₩101.17b

2.0x

P/S Ratio

-10.2x

P/E Ratio

Is A142760 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
A142760 income statement (TTM)
Revenue	₩101.17b
Cost of Revenue	₩75.65b
Gross Profit	₩25.52b
Other Expenses	₩45.29b
Earnings	-₩19.77b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-628.57
Gross Margin	25.23%
Net Profit Margin	-19.54%
Debt/Equity Ratio	58.8%

How did A142760 perform over the long term?

See historical performance and comparison

Valuation

Is Bioleaders undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

4.58x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A142760's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A142760's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: A142760 is unprofitable, so we can't compare its PE Ratio to the KR Biotechs industry average.

PE vs Market: A142760 is unprofitable, so we can't compare its PE Ratio to the KR market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A142760's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: A142760 is overvalued based on its PB Ratio (4.6x) compared to the KR Biotechs industry average (3.3x).

Future Growth

How is Bioleaders forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

13.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioleaders has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Bioleaders performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-20.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A142760 is currently unprofitable.

Growing Profit Margin: A142760 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: A142760 is unprofitable, and losses have increased over the past 5 years at a rate of 20.4% per year.

Accelerating Growth: Unable to compare A142760's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A142760 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20.1%).

Return on Equity

High ROE: A142760 has a negative Return on Equity (-36.38%), as it is currently unprofitable.

Financial Health

How is Bioleaders's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: A142760's short term assets (₩97.1B) exceed its short term liabilities (₩46.7B).

Long Term Liabilities: A142760's short term assets (₩97.1B) exceed its long term liabilities (₩43.8B).

Debt to Equity History and Analysis

Debt Level: A142760 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if A142760's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A142760 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: A142760 has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 12.5% each year.

Dividend

What is Bioleaders's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A142760's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A142760's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A142760's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A142760's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A142760 has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Andy Chul

no data

Tenure

Park Young Chul, also known as Andy is Chief Executive Officer & Chairman of Bioleaders Corporation. Park Young Chul Experience includes- Former CEO of Next Bio Technology Co., Ltd; Former CEO of TCM Biosc...

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.7%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/17 00:00
End of Day Share Price	2022/05/17 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31